Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer

Journal of Immunological Methods

Volumn 426, Issue , 2015, Pages 1-13

  Augustine, Tanya N ^a   Dix Peek, Thérèse ^a   Duarte, Raquel ^a   Candy, Geoffrey P ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Breast cancer; Matrigel; Natural killer cells; Regulatory T cells; Three dimensional culture

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; GLYCOPROTEIN; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MUCIN 1; PHYTOHEMAGGLUTININ; PROTEINASE K; RNA; CCL4 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CD4+ CD25+ T LYMPHOCYTE; CELL CULTURE; CELL INTERACTION; CELL INVASION; CELL ISOLATION; CELL SELECTION; CELL STRUCTURE; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HETEROTYPIC THREE DIMENSIONAL CULTURE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; MCF 7 CELL LINE; MONOLAYER CULTURE; NATURAL KILLER CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; RNA EXTRACTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; BREAST TUMOR; CELL COMMUNICATION; CULTURE TECHNIQUE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PROCEDURES; SECRETION (PROCESS); TUMOR MICROENVIRONMENT;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CHEMOKINE CCL4; ENDOPEPTIDASE K; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MCF-7 CELLS; MUCIN-1; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84949323515     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.07.003     Document Type: Article

References (95)

1. Acconcia F., Kumar R. Signaling regulation of genomic and nongenomic functions of oestrogen receptors. Cancer Lett. 2006, 238:1.
2. Adamczyk K.A., Klein-Scory S., Moradian M., Warnken U., Schmiegel W., Schnölzer M., Schwarte-waldhoff I. Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sci. 2011, 89(9-10):304.
3. Albertsson P.A., Basse P.H., Hokland M., Goldfarb R.H., Nagelkerke J.F., Nannmark U., Kuppen P.J.K. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 2003, 24(11):603.
4. Albertsson P.A., Basse P.H., Edsparr K., Kim M.H., Golfarb R.H., Kitson R.P., Lennernäs B., Nannmark U., Johansson B.R. Differential locomotion of long- and short-term IL-2-activated murine natural killer cells in a model matrix environment. Scand. J. Immunol. 2007, 66:402.
5. Ampuja M., Jokimäki R., Juuti-Uusitalo K., Rodriguez-Martinez A., Alarmo E.L., Kallioniemi A. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer 2013, 13:429.
6. Ascierto M.L., Idowu M.O., Zhao Y., Khalak H., Payne K.K., Wang X., Dumur C.I., Bedognetti D., Tomei S., Ascierto P.A., Shanker A., Bear H.D., Wang E., Marincola F.M., De Maria A., Manjili M.H. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J. Transl. Med. 2013, 11(1):145.
7. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., Banham A.H. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 2008, 24(34):5373.
8. Ben-Baruch A. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor - microenvironment interactions. Breast Cancer Res. 2003, 5:31.
9. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804.
10. Björnström L., Sjöberg M. Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl. Recept. 2004, 2:3.
11. Bohling S.D., Allison K.H. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod. Pathol. 2008, 21(12):1527.
12. Bottino C., Biassoni R., Millo R., Moretta L., Moretta A. The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum. Immunol. 2000, 61:1.
13. Brand T.M., Iida M., Luthar N., Starr M.M., Huppert E.J., Wheeler D.L. Nuclear EGFR as a molecular target in cancer. Radiother. Oncol. 2013, 108(3):370.
14. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: Minimum Information for publication of Quantitative real-time PCR Experiments. Clin. Chem. 2009, 55(4):611.
15. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., Guertin D.A., Chang J.H., Lindquist R.A., Moffat J., Golland P., Sabatini D.M. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006, 7:R100. 10.1186/gb-2006-7-10-r100.
16. Chambers B.J. NK cell-T cell interactions. Natural Killer Cells, Basic Science and Clinical Application 2010, 297. Academic Press Elsevier Ltd., London. M.T. Lotze, A.W. Thomson (Eds.).
17. Chandrasekaran S., Geng Y., DeLouise L., King M.R. Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines. Biomaterials 2012, 33(35):9037.
18. Cheng G., Aixin Y., Malek T.R. T-cell tolerance and the multi-functional role of IL-2R signalling in T-regulatory cells. Immunol. Rev. 2011, 241:63.
19. Chikileva I.O., Shubina I.Z., Baronzio G., Kiselevsky M.V. Is it necessary to deplete the lymphokine activated killers' populations of CD4+CD25+ lymphocytes? Regulatory Foxp3-positive T cells within lymphokine activated killers. Biomed. Pharmacother. 2010, 64:379.
20. Cimino-Mathews A., Ye X., Meeker A., Argani P., Emens L. Metastatic triple-negative breast cancers at first relapse have fewer tumour-infiltrating lymphocytes than their matched primary breast tumours: a pilot study. Hum. Pathol. 2013, 44(10):2055.
21. de Visser K., Coussens L. The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol. Immunother. 2005, 25:1143.
22. Decker T., Fischer G., Bücke W., Bücke P., Stotz F., Grüneberger A., Gropp-Meier M., Wiedemann G., Pfeiffer C., Peschel C., Götze K. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J. Cancer Res. Clin. Oncol. 2012, 138(11):1945.
23. Dewan Z., Takada M., Terunuma H., Deng X., Ahmed S., Yamamoto N., Toi M. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed. Pharmacother. 2009, 63(9):703.
24. Dhasarathy A., Kajita M., Wade P.A. The transcription factor Snail mediates epithelial to mesenchymal transitions by repression of oestrogen receptor alpha. Mol. Endocrinol. 2007, 21(12):2907.
25. do Amaral J.B., Rezende-Teixeira P., Freitas V.M., Machado-Santelli G.M. MCF-7 cells as a three-dimensional model for the study of human breast cancer. Tissue Eng. C 2011, 17(11):1097.
26. Domaica C.I., Fuertes M.B., Rossi L.E., Rabinovich G.A., Zwirner N.W. Tumour experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands. EMBO Rep. 2009, 10:908.
27. Drescher K.M., Lynch H.T. Tumour infiltrating lymphocytes (TILs): lessons learned in 30years of study. Clin. Appl. Immunol. Rev. 2005, 5:149.
28. Edsparr K., Speetjens F.M., Mulder-Stapel A., Goldfarb R.H., Basse P.H., Lennernäs B., Kuppen P.J.K., Albertsson P. Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT1. J. Immunother. 2010, 33(5):475.
29. Edsparr K., Basse P.H., Goldfarb R.H., Albertsson P. Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation. Cancer Microenviron. 2011, 4:351.
30. Elstner E., Muller C., Koshizuka K., Wimmilianson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., Koeffler H.P. Ligands for peroxisome proliferator-activated receptor y and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(July):8806.
31. Emens L.A., Silverstein S.C., Khleif S., Marincola F.M., Galon J. Toward integrative cancer immunotherapy: targeting the tumour microenvironment. J. Transl. Med. 2012, 10(1):70. 10.1186/1479-5876-10-70.
32. Engelmann K., Shen H., Finn O.J. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumour antigen MUC1. Cancer Res. 2008, 68:2419.
33. Fauriat C., Long E.O., Ljunggren H.G., Bryceson Y.T. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115(11):2167.
34. Foley J., Nickerson N.K., Nam S., Tan K., Gilmore J.L., Nephew K.P., Riese D.J. EGFR signalling in breast cancer: bad to the bone. Semin. Cell Dev. Biol. 2010, 21(9):951.
35. Georgiannos S.N., Renaut A., Goode A.W., Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 2003, 134:827.
36. Ghiringhelli F., Ménard C., Terme M., Flament C., Taieb J., Chaput N., Puig P.E., Novault S., Escudier B., Vivier E., Lecesne A., Robert C., Blay J., Bernard J., Caillat-Zucman S., Freitas A., Tursz T., Wagner-Ballon O., Capron C., Vainchencker W., Martin F., Zitvogel L. CD4 CD25 regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 2005, 202(8):1075.
37. Gil J.F., Augustine T.N., Hosie M.J. Anastrozole and RU486: effects on estrogen receptor α and Mucin 1 expression and correlation in the MCF-7 breast cancer cell line. Acta Histochem. 2013, 115:851.
38. Graham J.D., Mote P.A., Salagame U., Balleine R.L., Huschtscha L.I., Clarke C.L. Hormone-responsive model of primary human breast epithelium. J. Mammary Gland Biol. Neoplasia 2009, 14:367.
39. Gumuskaya B., Alper M., Hucumenoglu S., Altundag K., Uner A., Guler G. EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet. Cytogenet. 2010, 203(2):222.
40. Han J., Chang H., Giricz O., Lee G.Y., Baehner F.L., Gray J.W., Bissell M.J., Kenny P.A., Parvin B. Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput. Biol. 2010, 6(2):e1000684. 10.1371/journal.pcbi.1000684.
41. Herrera M.B., Bruno S., Buttiglieri S., Tetta C., Gatti S., Deregibus M.C., Bussolati B., Camussi G. Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006, 24:2840.
42. Hoover R.G., Gullickson G., Kornbluth J. Natural killer lytic-associated molecule plays a role in controlling tumour dissemination and metastasis. Front. Immunol. 2012, 3:393. 10.3389/fimmu.2012.0039.
43. Jin Q., Yuan L.X., Boulbes D., Baek J.M., Wang Y.N., Gomez-cabello D., Hawke D.H., Yeung S.C., Lee M.H., Hortobagyi G.N., Hung M.C., Esteva F.J. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010, 12(6):R96. 10.1186/bcr2777.
44. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R. Molecular profiling of breast cancer cell lines defines relevant tumour models and provides a resource for cancer gene discovery. PLoS ONE 2009, 4(7):e6146. 10.1371/journal.pone.0006146.
45. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1(1):84.
46. Khodarev N.N., Pitroda S.P., Beckett M.A., Macdermed D.M., Huang L., Kufe D.W., Weichselbaum R.R. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009, 69(7):2833.
47. Kleinman H.K., Martin G.R. Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol. 2005, 15:378.
48. Krause S., Maffini M.V., Soto A.M., Sonnenschein C. The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 2010, 10:263.
49. Kumar R., Wang R., Mazumdar A., Talukder A.H., Mandal M., Yang Z., Bagheri-Yarmand R., Sahin A., Hortobagyi G.N., Adam L., Barnes C.J., Vadlamudi R.K. A naturally occurring MTA1 variant sequesters oestrogen receptor-a in the cytoplasm. Nature 2002, 418(August):256.
50. Lechner M., Lirk P., Rieder J. Inducible nitric oxide synthase (iNOS) in tumour biology: the two sides of the same coin. Semin. Cancer Biol. 2005, 15:277.
51. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. 3D culture models of normal and malignant breast epithelial cells. Nature Methods 2007, 4(4):359.
52. Lee S.K., Kim J.Y., Jang B.W., Hur S.E., Na B.J., Lee M., Fukui A., Gilman-Sachs A., Kwak-Kim J. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood. Hum. Immunol. 2011, 72(8):621.
53. Lostumbo A., Mehta D., Setty S., Nunez R. Flow cytometry: a new approach for the molecular profiling of breast cancer. Exp. Mol. Pathol. 2006, 80:46.
54. Macchetti A.H., Marana H.R.C., Silva J.S., De Andrade J.M., Ribeiro-Silva A., Bighetti S. Tumour-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics 2006, 61(3):203.
55. Mamessier E., Sylvain A., Thibult M., Houvenaeghel G., Jacquemier J., Castellano R., Gonçalves A., André P., Romagné F., Thibault G., Viens P., Birnbaum D., Bertucci F., Moretta A., Olive D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 2011, 121(9):3609.
56. Mamessier E., Pradel L.C., Thibult M.-L., Drevet C., Zouine A., Jacquemier J., Houvenaeghel G., Bertucci F., Birnbaum D., Olive D. Peripheral blood NK cells from breast cancer patients are tumour-induced composite subsets. J. Immunol. 2013, 190(5):2424.
57. Mandapathil M., Lang S., Gorelik E., Whiteside T.L. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J. Immunol. Methods 2009, 346(1-2):55.
58. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21(1):27.
59. Miller J.S. The biology of natural killer cells in cancer, infection, and pregnancy. Exp. Hematol. 2001, 29:1157.
60. dim NK cells. Blood 2010, 116:3689.
61. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57.
62. Mozaffari F., Lindemalm C., Choudhury A., Granstam-Björneklett H., Helander I., Lekander M., Mikaelsson E., Nilsso B., Ojutkangas M.-L., Osterborg A., Bergkvist L., Mellstedt H. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br. J. Cancer 2007, 97:105.
63. Naber H.P., Wiercinska E., ten Dijke P., van Laar T. Spheroid assay to measure TGF-β-induced invasion. J. Vis. Exp. 2011, 57:e3337. 10.3791/3337.
64. Nath S., Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 2014, 20(6):332.
65. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J., Tong F., Speed T., Spellman P.T., Devries S., Lapuk A., Wang N.J., Kuo W., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., Mccormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(December):515.
66. Nyga A., Cheema U., Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J. Cell Commun. Signal. 2011, 5:239.
67. Olsen C.J., Moreira J., Lukanidin E.M., Ambartsumian N.S. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer 2010, 10:444.
68. Piersma S.J., Welters M.J.P., Van Der Burg S.H. Tumour-specific regulatory T cells in cancer patients. Hum. Immunol. 2008, 69:241.
69. Pinto M., Jacobsen B.M., Horwitz K.B. An immunohistochemical method to study breast cancer cell subpopulations and their growth regulation by hormones in three-dimensional cultures. Cell 2011, 2(June):1.
70. Poincloux R., Collin O., Lizárraga F., Romao M., Debray M., Piel M., Chavrier P. Contractility of the cell rear drives invasion of breast tumour cells in 3D Matrigel. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(5):1943.
71. Pollard J.W., Iyengar P., Combs T.P., Shah S.J., Albanese C., Flanagan L., Tenniswood M.P., Guha C., Lisanti M.P., Pestell R.G., Scherer P.E. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003, 22:6408.
72. Pooi P., Mohammad R., Ibrahim N., Ithnin H., Abdullah M., Davis W.C., Seow H.F. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol. Lett. 2006, 102:229.
73. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2010, 5(1):1.
74. Prestwich R.J., Errington F., Hatfieldy P., Merrick A.E., Ilett E.J., Selby P.J., Melcher A.A. The immune system - is it relevant to cancer development, progression and treatment?. Clin. Oncol. 2008, 20:101.
75. Ralainirina N., Poli A., Michel T., Poos L., Emmanuel A., Hentges F., Zimmer J. Control of NK cell functions by CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 2007, 81:144.
76. Roberti M.P., Mordoh J., Levy E.M. Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front. Immunol. 2012, 3:375.
77. Robinson S.C., Coussens L.M. Soluble mediators of inflammation during tumour development. Adv. Cancer Res. 2005, 93:159.
78. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a Single Mechanism of Self-tolerance Causes 1995.
79. Salagianni M., Lekka E., Moustaki A., Iliopoulou E.G., Baxevanis C.N., Papamichail M., Perez S.a NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J. Immunol. 2011, 186(6):3327.
80. Sanchez C., Le Treut T., Boehrer A., Knoblauch B., Imbert J., Olive D., Costello R. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol. Immunother. 2010, 60(1):1.
81. Selander K.S., Li L., Watson L., Merrell M., Dahmen H., Heinrich P.C., Harris K.W. Inhibition of gp130 signalling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res. 2004, 64:6924.
82. Sharan S., Nikhil K., Roy P. Effects of low dose treatment of tributyltin on the regulation of oestrogen receptor functions in MCF-7 cells. Toxicol. Appl. Pharmacol. 2013, 269:176.
83. Smyth M.J., Cretney E., Kelly J.M., Westwood J.A., Street S.E.A., Yagita H., Takeda K., van Dommelen Serani L.H., Degli-Esposti M.A., Hayakawa Y. Activation of NK cell cytotoxicity. Mol. Immunol. 2005, 42:501.
84. Tate C.R., Rhodes L.V., Segar H.C., Driver J.L., Pounder F.N., Burow M.E., Collins-Burow B.M. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012, 14(3):R79. 10.1186/bcr3192.
85. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., Tamai S., Matsubara O., Hatsuse K., Mochizuki H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumour aggressiveness. Pancreas 2004, 29(1):1.
86. Vicari A.P., Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002, 13:143.
87. Wei X., Xu H., Kufe D. MUC1 oncoprotein stabilizes and activates oestrogen receptor α. Mol. Cell 2006, 21:295.
88. West N.R., Kost S.E., Martin S.D., Milne K., Deleeuw R.J., Nelson B.H., Watson P.H. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 2013, 108(1):155.
89. Whiteside T.L. What are regulatory T cells (Treg) regulating in cancer and why?. Semin. Cancer Biol. 2012, 22:327.
90. Whiteside T.L., Jost L.M., Herberman B. Tumour-infiltrating lymphocytes: potential and limitations to their use for cancer therapy. Crit. Rev. Oncol. Hematol. 1992, 12:25.
91. Wilk E., Kalippke K., Buyny S., Schmidt R.E., Jacobs R. New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles. Immunobiology 2008, 213:271.
92. Ye Q., Kantonen S., Gomez-Cambronero J. Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. J. Mol. Biol. 2013, 425:755.
93. Yu P., Fu Y. Tumour-infiltrating T lymphocytes: friends or foes?. Lab. Investig. 2006, 86:231.
94. Yu X., Machesky L.M. Cells assemble invadopodia-like structures and invade into Matrigel in a matrix metalloprotease dependent manner in the circular invasion assay. PLoS ONE 2012, 7(2):e30605. 10.1371/journal.pone.0030605.
95. Zhang H., Grizzle W.E. Exosomes and cancer: a newly described pathway of immune suppression. Clin. Cancer Res. 2011, 17:959.